+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Cancer Cachexia - Global Market Trajectory & Analytics

  • PDF Icon

    Report

  • 255 Pages
  • March 2022
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5309861

Global Cancer Cachexia Market to Reach US$2.9 Billion by the Year 2027


Amid the COVID-19 crisis, the global market for Cancer Cachexia estimated at US$2.1 Billion in the year 2020, is projected to reach a revised size of US$2.9 Billion by 2027, growing at a CAGR of 4.7% over the analysis period 2020-2027. Progestogens, one of the segments analyzed in the report, is projected to grow at a 4.8% CAGR to reach US$1.2 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Corticosteroids segment is readjusted to a revised 4.2% CAGR for the next 7-year period. This segment currently accounts for a 24.7% share of the global Cancer Cachexia market.



The U.S. Accounts for Over 40.1% of Global Market Size in 2020, While China is Forecast to Grow at a 6.7% CAGR for the Period of 2020-2027


The Cancer Cachexia market in the U.S. is estimated at US$856.9 Million in the year 2020. The country currently accounts for a 40.07% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$252.5 Million in the year 2027 trailing a CAGR of 6.7% through 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.6% and 4.1% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.5% CAGR while Rest of European market (as defined in the study) will reach US$252.5 Million by the year 2027.

Combination Therapies Segment Corners a 21.6% Share in 2020


In the global Combination Therapies segment, USA, Canada, Japan, China and Europe will drive the 5.6% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$396.7 Million in the year 2020 will reach a projected size of US$581.2 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$211.8 Million by the year 2027.

Select Competitors (Total 50 Featured) -

  • AstraZeneca plc
  • AVEO Pharmaceuticals, Inc.
  • Boehringer Ingelheim International GmbH
  • Eli Lilly and Company
  • Helsinn Healthcare SA
  • INOVIO Pharmaceuticals
  • Marsala Biotech Inc.
  • MetaFines Co., Ltd.

What's New for 2022?

  • Global competitiveness and key competitor percentage market shares
  • Market presence across multiple geographies - Strong/Active/Niche/Trivial
  • Online interactive peer-to-peer collaborative bespoke updates
  • Access to the publisher's digital archives and Research Platform
  • Complimentary updates for one year
Frequently Asked Questions about the Global Market for Cancer Cachexia

What is the estimated value of the Global Market for Cancer Cachexia?

The Global Market for Cancer Cachexia was estimated to be valued at $2.1 Billion in 2020.

What is the growth rate of the Global Market for Cancer Cachexia?

The growth rate of the Global Market for Cancer Cachexia is 4.7%, with an estimated value of $2.9 Billion by 2027.

What is the forecasted size of the Global Market for Cancer Cachexia?

The Global Market for Cancer Cachexia is estimated to be worth $2.9 Billion by 2027.

Who are the key companies in the Global Market for Cancer Cachexia?

Key companies in the Global Market for Cancer Cachexia include AstraZeneca plc, AVEO Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH., Eli Lilly and Company, Helsinn Healthcare SA, INOVIO Pharmaceuticals and MetaFines Co., Ltd..

Table of Contents

I. METHODOLOGY


II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

  • Cancer: An Insight
  • A Prelude to Cancer Cachexia
  • Cachexia Treatment
  • Pharmacologic Approaches for Clinical Management of Cancer Cachexia
  • Impact of Covid-19 and a Looming Global Recession
  • A Review of COVID-19 Pandemic and its Impact on World Economy
  • With IMF Making an Upward Revision of Global GDP for 2022, Companies Remain Bullish About an Economic Comeback
  • EXHIBIT 1: World Economic Growth Projections (Real GDP, Annual % Change) for 2020 through 2022
  • Cancer Cachexia Market Faces a Challenge Amid the Pandemic
  • EXHIBIT 2: Percentage YoY Change in Sales of Select Physician-Administered Oncology Products Chemotherapy Administration: (March-June) 2019 Vs 2020March
  • Pandemic Impact on Cancer Research
  • Global Market Prospects and Outlook
  • Progestogens Account for a Major Share, Combination Therapies to Drive Growth
  • North America and Europe Constitute Major Regions, Asia-Pacific Exhibits the Fastest Growth
  • Competition
  • EXHIBIT 3: Cancer Cachexia - Global Key Competitors Percentage Market Share in 2022 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for 29 Players Worldwide in 2022 (E)
  • Recent Market Activity
  • Market Challenges

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

  • Rise in Number of Cancer Cases, and High Prevalence of Cancer Cachexia to Drive Market Growth
  • EXHIBIT 4: Breakdown of Total Number of Cancer Cases by Region: 2020
  • EXHIBIT 5: Breakdown of Total Number of Cancer Cases by Type: 2020
  • EXHIBIT 6: Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
  • Numerous Efforts Underway to Improve Therapy for Cancer Presents Lucrative Opportunities
  • Promising Treatment Options Drive Market Gains
  • NSAID
  • Erythropoietin
  • IL-1a, IL-6 & TNFa Inhibitors
  • Myostatin Inhibitors
  • Appetite & Metabolism Modulators
  • Cytokine Modulator
  • Anabolic Agents
  • Combination Therapies
  • DNA Link to throw More Light on Cancer Cachexia
  • Ageing Demographics to Drive Market Demand
  • EXHIBIT 7: Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
  • EXHIBIT 8: Elderly Population (65+ Years) as a % of Total Population by Developed, Less Developed and Least Developed Regions: 2019 & 2030
  • EXHIBIT 9: Estimated Number of New Cancer Cases in 2020 for Age Group 65-84
  • Cancer Research Spending Continues to Witness Growth
  • EXHIBIT 10: Number of FDA-Approved Cancer Drugs: 2010-2018
  • EXHIBIT 11: Increasing Share of Cancer Drugs as % Of Total Pharma Drug Pipeline: 2010-2019
  • EXHIBIT 12: NCI Funding for Cancer Research (2002, 2008, 2014 and 2020)
  • Pipeline Analysis
  • Macimorelin from AEterna Zentaris
  • PF- 06946860 from Pfizer
  • TCMCB07 from Endevica Bio
  • Actimed Therapeutics S-pindolol
  • Lenalidomide
  • AV-380
  • Select Unimodal Treatment Agents for Cancer Cachexia Currently Under Clinical Trial
  • Combination of Medical Therapeutics and Nutritional Interventions to Provide Better Outcome
  • Select Key Developments
  • Helsinn Launches Adlumiz for Cancer Cachexia Patients in Japan
  • Researchers Secure Program Project Grant to Uncover Biology behind Cancer Cachexia
  • Researchers Develop New Drug with Potential to Improve & Treat Cancer Cachexia
  • Actimed Therapeutics Plans to Advance Lead Compound for Cancer Cachexia
  • ESMO Publishes New Guidelines on Cachexia Management in Adult Cancer Patients
  • Uptrend in Healthcare Spending Drives Market Demand
  • EXHIBIT 13: World Healthcare Expenditure (In US$ Billion) for the Years 2017-2023
  • EXHIBIT 14: Healthcare Costs as a % of GDP by Country for the Years 2020 & 2023
  • EXHIBIT 15: World Healthcare Expenditure by Disease/Health Condition: 2021

4. GLOBAL MARKET PERSPECTIVE

  • TABLE 1: World Recent Past, Current & Future Analysis for Cancer Cachexia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • TABLE 2: World Historic Review for Cancer Cachexia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • TABLE 3: World 15-Year Perspective for Cancer Cachexia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2021 & 2027
  • TABLE 4: World Recent Past, Current & Future Analysis for Progestogens by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • TABLE 5: World Historic Review for Progestogens by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • TABLE 6: World 15-Year Perspective for Progestogens by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
  • TABLE 7: World Recent Past, Current & Future Analysis for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • TABLE 8: World Historic Review for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • TABLE 9: World 15-Year Perspective for Corticosteroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
  • TABLE 10: World Recent Past, Current & Future Analysis for Combination Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • TABLE 11: World Historic Review for Combination Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • TABLE 12: World 15-Year Perspective for Combination Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
  • TABLE 13: World Recent Past, Current & Future Analysis for Other Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • TABLE 14: World Historic Review for Other Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • TABLE 15: World 15-Year Perspective for Other Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
  • TABLE 16: World Recent Past, Current & Future Analysis for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • TABLE 17: World Historic Review for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • TABLE 18: World 15-Year Perspective for Hospital Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
  • TABLE 19: World Recent Past, Current & Future Analysis for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • TABLE 20: World Historic Review for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • TABLE 21: World 15-Year Perspective for Retail Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
  • TABLE 22: World Recent Past, Current & Future Analysis for Online Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • TABLE 23: World Historic Review for Online Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • TABLE 24: World 15-Year Perspective for Online Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027

III. MARKET ANALYSIS

UNITED STATES

  • Cancer Cachexia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2022 (E)
  • Market Analytics
  • TABLE 25: USA Recent Past, Current & Future Analysis for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • TABLE 26: USA Historic Review for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • TABLE 27: USA 15-Year Perspective for Cancer Cachexia by Therapeutics - Percentage Breakdown of Value Sales for Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics for the Years 2012, 2021 & 2027
  • TABLE 28: USA Recent Past, Current & Future Analysis for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • TABLE 29: USA Historic Review for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • TABLE 30: USA 15-Year Perspective for Cancer Cachexia by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027

CANADA

  • TABLE 31: Canada Recent Past, Current & Future Analysis for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • TABLE 32: Canada Historic Review for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • TABLE 33: Canada 15-Year Perspective for Cancer Cachexia by Therapeutics - Percentage Breakdown of Value Sales for Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics for the Years 2012, 2021 & 2027
  • TABLE 34: Canada Recent Past, Current & Future Analysis for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • TABLE 35: Canada Historic Review for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • TABLE 36: Canada 15-Year Perspective for Cancer Cachexia by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027

JAPAN

  • TABLE 37: Japan Recent Past, Current & Future Analysis for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • TABLE 38: Japan Historic Review for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • TABLE 39: Japan 15-Year Perspective for Cancer Cachexia by Therapeutics - Percentage Breakdown of Value Sales for Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics for the Years 2012, 2021 & 2027
  • TABLE 40: Japan Recent Past, Current & Future Analysis for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • TABLE 41: Japan Historic Review for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • TABLE 42: Japan 15-Year Perspective for Cancer Cachexia by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027

CHINA

  • TABLE 43: China Recent Past, Current & Future Analysis for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • TABLE 44: China Historic Review for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • TABLE 45: China 15-Year Perspective for Cancer Cachexia by Therapeutics - Percentage Breakdown of Value Sales for Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics for the Years 2012, 2021 & 2027
  • TABLE 46: China Recent Past, Current & Future Analysis for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • TABLE 47: China Historic Review for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • TABLE 48: China 15-Year Perspective for Cancer Cachexia by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027

EUROPE

  • Cancer Cachexia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2022 (E)
  • Market Analytics
  • TABLE 49: Europe Recent Past, Current & Future Analysis for Cancer Cachexia by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
  • TABLE 50: Europe Historic Review for Cancer Cachexia by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • TABLE 51: Europe 15-Year Perspective for Cancer Cachexia by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2021 & 2027
  • TABLE 52: Europe Recent Past, Current & Future Analysis for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • TABLE 53: Europe Historic Review for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • TABLE 54: Europe 15-Year Perspective for Cancer Cachexia by Therapeutics - Percentage Breakdown of Value Sales for Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics for the Years 2012, 2021 & 2027
  • TABLE 55: Europe Recent Past, Current & Future Analysis for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • TABLE 56: Europe Historic Review for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • TABLE 57: Europe 15-Year Perspective for Cancer Cachexia by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027

FRANCE

  • TABLE 58: France Recent Past, Current & Future Analysis for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • TABLE 59: France Historic Review for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • TABLE 60: France 15-Year Perspective for Cancer Cachexia by Therapeutics - Percentage Breakdown of Value Sales for Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics for the Years 2012, 2021 & 2027
  • TABLE 61: France Recent Past, Current & Future Analysis for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • TABLE 62: France Historic Review for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • TABLE 63: France 15-Year Perspective for Cancer Cachexia by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027

GERMANY

  • TABLE 64: Germany Recent Past, Current & Future Analysis for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • TABLE 65: Germany Historic Review for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • TABLE 66: Germany 15-Year Perspective for Cancer Cachexia by Therapeutics - Percentage Breakdown of Value Sales for Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics for the Years 2012, 2021 & 2027
  • TABLE 67: Germany Recent Past, Current & Future Analysis for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • TABLE 68: Germany Historic Review for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • TABLE 69: Germany 15-Year Perspective for Cancer Cachexia by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027

ITALY

  • TABLE 70: Italy Recent Past, Current & Future Analysis for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • TABLE 71: Italy Historic Review for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • TABLE 72: Italy 15-Year Perspective for Cancer Cachexia by Therapeutics - Percentage Breakdown of Value Sales for Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics for the Years 2012, 2021 & 2027
  • TABLE 73: Italy Recent Past, Current & Future Analysis for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • TABLE 74: Italy Historic Review for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • TABLE 75: Italy 15-Year Perspective for Cancer Cachexia by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027

UNITED KINGDOM

  • TABLE 76: UK Recent Past, Current & Future Analysis for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • TABLE 77: UK Historic Review for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • TABLE 78: UK 15-Year Perspective for Cancer Cachexia by Therapeutics - Percentage Breakdown of Value Sales for Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics for the Years 2012, 2021 & 2027
  • TABLE 79: UK Recent Past, Current & Future Analysis for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • TABLE 80: UK Historic Review for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • TABLE 81: UK 15-Year Perspective for Cancer Cachexia by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027

REST OF EUROPE

  • TABLE 82: Rest of Europe Recent Past, Current & Future Analysis for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • TABLE 83: Rest of Europe Historic Review for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • TABLE 84: Rest of Europe 15-Year Perspective for Cancer Cachexia by Therapeutics - Percentage Breakdown of Value Sales for Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics for the Years 2012, 2021 & 2027
  • TABLE 85: Rest of Europe Recent Past, Current & Future Analysis for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • TABLE 86: Rest of Europe Historic Review for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • TABLE 87: Rest of Europe 15-Year Perspective for Cancer Cachexia by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027

ASIA-PACIFIC

  • TABLE 88: Asia-Pacific Recent Past, Current & Future Analysis for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • TABLE 89: Asia-Pacific Historic Review for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • TABLE 90: Asia-Pacific 15-Year Perspective for Cancer Cachexia by Therapeutics - Percentage Breakdown of Value Sales for Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics for the Years 2012, 2021 & 2027
  • TABLE 91: Asia-Pacific Recent Past, Current & Future Analysis for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • TABLE 92: Asia-Pacific Historic Review for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • TABLE 93: Asia-Pacific 15-Year Perspective for Cancer Cachexia by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027

REST OF WORLD

  • TABLE 94: Rest of World Recent Past, Current & Future Analysis for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • TABLE 95: Rest of World Historic Review for Cancer Cachexia by Therapeutics - Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • TABLE 96: Rest of World 15-Year Perspective for Cancer Cachexia by Therapeutics - Percentage Breakdown of Value Sales for Progestogens, Corticosteroids, Combination Therapies and Other Therapeutics for the Years 2012, 2021 & 2027
  • TABLE 97: Rest of World Recent Past, Current & Future Analysis for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
  • TABLE 98: Rest of World Historic Review for Cancer Cachexia by End-Use - Hospital Pharmacy, Retail Pharmacy and Online Pharmacy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
  • TABLE 99: Rest of World 15-Year Perspective for Cancer Cachexia by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Online Pharmacy for the Years 2012, 2021 & 2027

IV. COMPETITION

  • Total Companies Profiled: 50

Companies Mentioned

A selection of companies mentioned in this report includes:

  • AstraZeneca plc
  • AVEO Pharmaceuticals, Inc.
  • Boehringer Ingelheim International GmbH
  • Eli Lilly and Company
  • Helsinn Healthcare SA
  • INOVIO Pharmaceuticals
  • Marsala Biotech Inc.
  • MetaFines Co., Ltd.